The Value of Combining Wu Ling San Plus and Minus with Repaglinide in the Treatment of Obese Type 2 Diabetes

Abstract

Objective: To investigate the clinical value and practical effects of the treatment of obese type 2 diabetes mellitus patients with Wu Ling San plus and minus combined with Repaglinide. Methods: Twenty-two obese type 2 diabetic patients attending the outpatient clinic of Yixing Traditional Chinese Medicine Hospital from September 2020 to March 2022 were randomly selected as the subjects of this study, and all of them were divided into treatment group (n=11, Wu Ling San plus and minus + Repaglinide) and control group (n=11, single Repaglinide) according to the computerized random series grouping method. The clinical data and overall efficacy of the two groups were compared. Results: After treatment, the treatment group had better blood glucose, blood lipids and other basic indicators than the control group (P<0.05); all Chinese medicine symptoms scores and complication rates of the treatment group were lower than those of the control group (P<0.05). Conclusion: The treatment of obese type 2 diabetes mellitus patients with Wu Ling San plus reduction + Repaglinide has significant efficacy and high drug safety, and can stabilize many indicators of blood glucose and blood lipids, reduce the risk of complications and control their body weight, which can be promoted and used in the treatment of related clinical conditions.